Update shared on04 Sep 2025
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00.
What's in the News
- Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.
- The certification enables streamlined regulatory approval across the U.S., Canada, Brazil, Japan, and Australia.
- MDSAP is expected to reduce approval timelines and costs in multiple jurisdictions.
- The move enhances Sensus' ability to expand international commercial operations and engage with global hospital systems and clinics.
Valuation Changes
Summary of Valuation Changes for Sensus Healthcare
- The Consensus Analyst Price Target remained effectively unchanged, at $8.00.
- The Discount Rate for Sensus Healthcare remained effectively unchanged, at 7.48%.
- The Future P/E for Sensus Healthcare remained effectively unchanged, at 16.60x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.